FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892986183> ?p ?o ?g. }

• W2892986183 endingPage "34288" @default.
• W2892986183 startingPage "34279" @default.
• W2892986183 abstract "// Sofía del Carmen 1, * , José María Sayagués 2, * , Oscar Bengoechea 1 , María Fernanda Anduaga 3 , Jose Antonio Alcazar 3 , Ruth Gervas 1 , Jacinto García 3 , Alberto Orfao 2, ** , Luis Muñoz Bellvis 3, ** , María Eugenia Sarasquete 4, ** and María del Mar Abad 1, ** 1 Department of Pathology and IBSAL, University Hospital of Salamanca, Salamanca, Spain 2 Cytometry Service-NUCLEUS, Department of Medicine, Cancer Research Center (IBMCC-CSIC/USAL) and IBSAL, University Hospital of Salamanca, Salamanca, Spain 3 General and Gastrointestinal Surgery Service and IBSAL, University Hospital of Salamanca, Salamanca, Spain 4 Hematology Service, University Hospital of Salamanca, Salamanca, Spain * These authors have contributed equally to this work ** These authors have contributed equally to this work and they should be considered as senior last authors and corresponding authors Correspondence to: María Eugenia Sarasquete, email: mealonsos@saludcastillayleon.es María del Mar Abad, email: marabad@usal.es Keywords: colorectal cancer; clonal evolution; anti-EGFR; mutational profile; tumor heterogeneity Received: June 30, 2018      Accepted: August 10, 2018      Published: September 28, 2018 ABSTRACT It is well known that activating mutations in the KRAS and NRAS genes are associated with poor response to anti-EGFR therapies in patients with metastatic colorectal cancer (mCRC). Approximately half of the patients with wild-type (WT) KRAS colorectal carcinoma do not respond to these therapies. This could be because the treatment decision is determined by the mutational profile of the primary tumor, regardless of the presence of small tumor subclones harboring RAS mutations in lymph nodes or liver metastases. We analyzed the mutational profile of the KRAS , NRAS , BRAF and PI3KCA genes using low-density microarray technology in samples of 26 paired primary tumors, 16 lymph nodes and 34 liver metastases from 26 untreated mCRC patients (n=76 samples). The most frequent mutations found in primary tumors were KRAS (15%) and PI3KCA (15%), followed by NRAS (8%) and BRAF (4%). The distribution of the mutations in the 16 lymph node metastases analyzed was as follows: 4 (25%) in KRAS gene, 3 (19%) in NRAS gene and 1 mutation each in PI3KCA and BRAF genes (6%). As expected, the most prevalent mutation in liver metastasis was in the KRAS gene (35%), followed by PI3KCA (9%) and BRAF (6%). Of the 26 cases studied, 15 (58%) displayed an overall concordance in the mutation status detected in the lymph node metastases and liver metastases compared with primary tumor, suggesting no clonal evolution. In contrast, the mutation profiles differed in the primary tumor and lymph node/metastases samples of the remaining 11 patients (48%), suggesting a spatial and temporal clonal evolution. We confirm the presence of different mutational profiles among primary tumors, lymph node metastases and liver metastases. Our results suggest the need to perform mutational analysis in all available tumor samples of patients before deciding to commence anti-EGFR treatment." @default.
• W2892986183 created "2018-10-05" @default.
• W2892986183 creator A5014013713 @default.
• W2892986183 creator A5014092107 @default.
• W2892986183 creator A5037714238 @default.
• W2892986183 creator A5051937379 @default.
• W2892986183 creator A5056695728 @default.
• W2892986183 creator A5065497666 @default.
• W2892986183 creator A5067351937 @default.
• W2892986183 creator A5075795532 @default.
• W2892986183 creator A5087149819 @default.
• W2892986183 creator A5088215641 @default.
• W2892986183 creator A5090056802 @default.
• W2892986183 date "2018-09-28" @default.
• W2892986183 modified "2023-10-16" @default.
• W2892986183 title "Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach" @default.
• W2892986183 cites W1520183139 @default.
• W2892986183 cites W1652638408 @default.
• W2892986183 cites W1727309928 @default.
• W2892986183 cites W1757407923 @default.
• W2892986183 cites W1967325169 @default.
• W2892986183 cites W1974798136 @default.
• W2892986183 cites W1985035689 @default.
• W2892986183 cites W2001727709 @default.
• W2892986183 cites W2011288277 @default.
• W2892986183 cites W2011847340 @default.
• W2892986183 cites W2040674160 @default.
• W2892986183 cites W2056001934 @default.
• W2892986183 cites W2059852952 @default.
• W2892986183 cites W2076789869 @default.
• W2892986183 cites W2100543432 @default.
• W2892986183 cites W2103856575 @default.
• W2892986183 cites W2104580737 @default.
• W2892986183 cites W2106789440 @default.
• W2892986183 cites W2111905790 @default.
• W2892986183 cites W2114048774 @default.
• W2892986183 cites W2123303153 @default.
• W2892986183 cites W2127238742 @default.
• W2892986183 cites W2127248987 @default.
• W2892986183 cites W2128937710 @default.
• W2892986183 cites W2131371081 @default.
• W2892986183 cites W2134142320 @default.
• W2892986183 cites W2134519717 @default.
• W2892986183 cites W2135449254 @default.
• W2892986183 cites W2142097336 @default.
• W2892986183 cites W2155014687 @default.
• W2892986183 cites W2155311724 @default.
• W2892986183 cites W2162247266 @default.
• W2892986183 cites W2301065828 @default.
• W2892986183 cites W2470575266 @default.
• W2892986183 cites W2557660307 @default.
• W2892986183 cites W4250745281 @default.
• W2892986183 doi "https://doi.org/10.18632/oncotarget.26081" @default.
• W2892986183 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6188146" @default.
• W2892986183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30344942" @default.
• W2892986183 hasPublicationYear "2018" @default.
• W2892986183 type Work @default.
• W2892986183 sameAs 2892986183 @default.
• W2892986183 citedByCount "14" @default.
• W2892986183 countsByYear W28929861832019 @default.
• W2892986183 countsByYear W28929861832020 @default.
• W2892986183 countsByYear W28929861832021 @default.
• W2892986183 countsByYear W28929861832022 @default.
• W2892986183 countsByYear W28929861832023 @default.
• W2892986183 crossrefType "journal-article" @default.
• W2892986183 hasAuthorship W2892986183A5014013713 @default.
• W2892986183 hasAuthorship W2892986183A5014092107 @default.
• W2892986183 hasAuthorship W2892986183A5037714238 @default.
• W2892986183 hasAuthorship W2892986183A5051937379 @default.
• W2892986183 hasAuthorship W2892986183A5056695728 @default.
• W2892986183 hasAuthorship W2892986183A5065497666 @default.
• W2892986183 hasAuthorship W2892986183A5067351937 @default.
• W2892986183 hasAuthorship W2892986183A5075795532 @default.
• W2892986183 hasAuthorship W2892986183A5087149819 @default.
• W2892986183 hasAuthorship W2892986183A5088215641 @default.
• W2892986183 hasAuthorship W2892986183A5090056802 @default.
• W2892986183 hasBestOaLocation W28929861831 @default.
• W2892986183 hasConcept C121608353 @default.
• W2892986183 hasConcept C126322002 @default.
• W2892986183 hasConcept C143998085 @default.
• W2892986183 hasConcept C21790070 @default.
• W2892986183 hasConcept C2781187634 @default.
• W2892986183 hasConcept C512399662 @default.
• W2892986183 hasConcept C526805850 @default.
• W2892986183 hasConcept C71924100 @default.
• W2892986183 hasConceptScore W2892986183C121608353 @default.
• W2892986183 hasConceptScore W2892986183C126322002 @default.
• W2892986183 hasConceptScore W2892986183C143998085 @default.
• W2892986183 hasConceptScore W2892986183C21790070 @default.
• W2892986183 hasConceptScore W2892986183C2781187634 @default.
• W2892986183 hasConceptScore W2892986183C512399662 @default.
• W2892986183 hasConceptScore W2892986183C526805850 @default.
• W2892986183 hasConceptScore W2892986183C71924100 @default.
• W2892986183 hasIssue "76" @default.
• W2892986183 hasLocation W28929861831 @default.
• W2892986183 hasLocation W28929861832 @default.
• W2892986183 hasLocation W28929861833 @default.
• W2892986183 hasLocation W28929861834 @default.

• next